Ondansetron Hexal: Uses, Dosage & Side Effects
Ondansetron hydrochloride dihydrate – Serotonin (5-HT3) Receptor Antagonist
Quick Facts About Ondansetron Hexal
Key Takeaways About Ondansetron Hexal
- Prevents chemotherapy-induced nausea: Ondansetron Hexal is one of the most widely used antiemetics for preventing nausea and vomiting caused by cancer chemotherapy, radiation, and surgery
- Works by blocking serotonin: It selectively blocks 5-HT3 receptors, preventing the chemical signals that trigger nausea and vomiting
- Maximum single IV dose is 16 mg: A single intravenous dose must not exceed 16 mg due to the risk of serious cardiac rhythm disturbances (QT prolongation)
- Do not use with apomorphine: Concurrent use with apomorphine is contraindicated due to risk of severe hypotension and loss of consciousness
- Avoid in first trimester of pregnancy: Ondansetron may slightly increase the risk of cleft lip and/or cleft palate when used in the first three months of pregnancy
What Is Ondansetron Hexal and What Is It Used For?
Ondansetron Hexal is a prescription antiemetic injection containing ondansetron, a serotonin 5-HT3 receptor antagonist. It is used to prevent and treat nausea and vomiting caused by chemotherapy, radiation therapy, and surgery in both adults and children.
Ondansetron Hexal belongs to a group of medicines called serotonin (5-HT3) receptor antagonists. These medications work by blocking the action of the chemical serotonin at specific receptor sites in the body. When chemotherapy drugs, radiation, or anesthesia trigger the release of large amounts of serotonin from specialized cells in the gut, this serotonin normally activates 5-HT3 receptors on nearby nerve endings, sending signals to the brain's vomiting center. Ondansetron intercepts these signals, effectively preventing the nausea and vomiting reflex before it starts.
Ondansetron was first developed in the 1980s and received regulatory approval in the early 1990s. It quickly became one of the most important advances in supportive cancer care, dramatically improving quality of life for patients undergoing chemotherapy and radiation. Today, ondansetron appears on the World Health Organization's List of Essential Medicines, reflecting its critical importance in global healthcare. The drug is available in multiple formulations worldwide, including tablets, oral solution, and the injectable form found in Ondansetron Hexal.
Uses in Adults
In adult patients, Ondansetron Hexal is administered intravenously for the prevention and treatment of nausea and vomiting associated with three main clinical scenarios. First, it is used before, during, and after chemotherapy treatment for cancer, where certain drugs such as cisplatin, cyclophosphamide, and doxorubicin are highly likely to cause severe nausea. Second, it is given to patients receiving radiation therapy, which can similarly trigger nausea through serotonin release. Third, it is used in the perioperative setting to prevent and treat postoperative nausea and vomiting (PONV), which is one of the most common complications of general anesthesia.
For chemotherapy-induced nausea and vomiting (CINV), ondansetron is often combined with other antiemetic agents as part of a multimodal regimen. International guidelines from organizations such as the Multinational Association of Supportive Care in Cancer (MASCC) and the American Society of Clinical Oncology (ASCO) recommend combining a 5-HT3 antagonist with a corticosteroid (typically dexamethasone) and, for highly emetogenic chemotherapy, a neurokinin-1 (NK1) receptor antagonist.
Uses in Children
Ondansetron Hexal is approved for use in pediatric patients. For chemotherapy-induced nausea and vomiting, it can be given to children aged 6 months and older. For prevention and treatment of postoperative nausea and vomiting, it is approved from 1 month of age. Dosing in children is calculated individually by the physician based on the child's body weight or body surface area, ensuring safe and effective treatment tailored to the pediatric patient.
Ondansetron Hexal is a hospital-administered medication. It is given by a doctor or nurse as an intravenous injection or infusion. After the initial injection, treatment typically continues with ondansetron tablets by mouth. Always follow your healthcare provider's specific instructions regarding dosing and duration of treatment.
What Should You Know Before Taking Ondansetron Hexal?
Before receiving Ondansetron Hexal, your healthcare provider needs to know about allergies to ondansetron or related drugs, any heart rhythm problems, liver disease, electrolyte imbalances, and all other medications you take. It must not be used with apomorphine and should be avoided in the first trimester of pregnancy.
As with any prescription medication, there are important safety considerations to be aware of before using Ondansetron Hexal. Your healthcare provider will assess whether this medication is appropriate for you based on your medical history, current medications, and individual risk factors. Being forthcoming about all relevant health information ensures the safest and most effective use of this treatment.
Contraindications
You must not receive Ondansetron Hexal if you have a known allergy to ondansetron or any of the other ingredients in this medicine, including citric acid monohydrate (E 330), sodium citrate dihydrate (E 331), sodium chloride, and water for injections. If you have previously experienced a hypersensitivity reaction to other 5-HT3 receptor antagonists such as granisetron or dolasetron, you may also be allergic to ondansetron and should inform your doctor.
Ondansetron Hexal must not be used if you are taking apomorphine, a medication used for Parkinson's disease. The combination can cause a dangerous drop in blood pressure (severe hypotension) and loss of consciousness. This is an absolute contraindication with no exceptions.
Warnings and Precautions
Talk to your doctor or pharmacist before receiving Ondansetron Hexal if any of the following apply to you:
- Bowel obstruction: If you have a blockage or partial blockage of the intestines (intestinal obstruction), ondansetron may mask the symptoms and delay diagnosis. Your doctor needs to monitor you closely.
- Liver impairment: If you have reduced liver function, the daily dose of Ondansetron Hexal should not exceed 8 mg for patients with moderate to severe hepatic impairment. The liver is the primary organ responsible for metabolizing ondansetron.
- Tonsillectomy: Following tonsillectomy surgery, tell your doctor you are receiving ondansetron as specific monitoring may be required.
- Heart problems: If you have cardiac arrhythmias (irregular heartbeat), congestive heart failure, or are taking medications for heart rhythm disorders. Ondansetron can cause QT prolongation, which is a change in the heart's electrical activity that can lead to a potentially dangerous abnormal heart rhythm.
- Electrolyte imbalances: If you have low potassium (hypokalemia), low magnesium (hypomagnesemia), or other electrolyte disturbances, these conditions can increase the risk of cardiac side effects.
- Serotonergic medications: If you are taking other drugs that affect the serotonin system (such as SSRIs or SNRIs for depression), there is a risk of developing serotonin syndrome, a potentially serious condition caused by excessive serotonin activity.
If you develop breathing problems while receiving this medication, contact your healthcare provider immediately as respiratory symptoms may be an early sign of a hypersensitivity reaction. While such reactions are rare, they can be serious and require prompt medical attention.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, you should discuss the risks and benefits of ondansetron with your healthcare provider before receiving treatment. Ondansetron Hexal should not be used during the first three months of pregnancy (first trimester). Research has shown that ondansetron may slightly increase the risk of a baby being born with a cleft lip and/or cleft palate (an opening or split in the upper lip or roof of the mouth).
Women of childbearing age may be advised to use effective contraception during treatment. If you are already pregnant and need antiemetic therapy, your doctor will consider alternative medications or weigh the benefits against the potential risks for your specific situation.
Ondansetron may pass into breast milk. If you are breastfeeding, Ondansetron Hexal should not be used unless specifically prescribed by your doctor after careful consideration of the potential effects on the nursing infant. Your physician will help you assess whether the benefits of treatment outweigh the potential risks to your baby.
Driving and Operating Machinery
Clinical studies suggest that ondansetron does not impair the ability to drive or operate machinery under normal circumstances. However, some patients may experience side effects such as blurred vision or dizziness that could affect these activities. You should assess your own fitness to drive or perform tasks requiring alertness, particularly when you first start treatment or when your dose is adjusted.
Ondansetron Hexal contains less than 1 mmol sodium (23 mg) per dose, meaning it is essentially sodium-free. This information is relevant for patients on a controlled sodium diet.
How Does Ondansetron Hexal Interact with Other Drugs?
Ondansetron Hexal interacts with several important medications. It must never be combined with apomorphine. Key interactions include reduced effectiveness with enzyme-inducing drugs (phenytoin, carbamazepine, rifampicin), reduced pain relief with tramadol, and risk of serotonin syndrome with SSRIs and SNRIs.
Drug interactions can alter how medications work and may increase the risk of serious side effects. It is essential to inform your healthcare provider about all medicines you are currently taking, have recently taken, or might be planning to take. This includes prescription drugs, over-the-counter medications, vitamins, and herbal supplements. The following table summarizes the most clinically significant interactions with Ondansetron Hexal.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Apomorphine (Parkinson's disease) | Severe hypotension, loss of consciousness | Absolutely contraindicated – do not use together |
| SSRIs (citalopram, fluoxetine, paroxetine, sertraline, escitalopram, fluvoxamine) | Risk of serotonin syndrome (agitation, tremor, hyperthermia, muscle rigidity) | Use with caution; monitor for symptoms of serotonin syndrome |
| SNRIs (venlafaxine, duloxetine) | Risk of serotonin syndrome | Use with caution; monitor closely |
| QT-prolonging drugs (certain antiarrhythmics, antibiotics, antipsychotics) | Additive QT prolongation, increased risk of arrhythmia | ECG monitoring recommended; correct electrolytes before use |
| Anthracyclines (doxorubicin, epirubicin) | Increased risk of cardiac arrhythmia | Cardiac monitoring advised during co-administration |
Minor Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Phenytoin (antiepileptic) | May reduce ondansetron blood levels through enzyme induction | Monitor antiemetic effectiveness; dose adjustment may be needed |
| Carbamazepine (antiepileptic) | May reduce ondansetron blood levels through enzyme induction | Monitor antiemetic effectiveness |
| Rifampicin (antibiotic for tuberculosis) | Significantly reduces ondansetron blood levels via CYP3A4 induction | May require alternative antiemetic or dose adjustment |
| Tramadol (analgesic) | Reduced analgesic (pain-relieving) effect of tramadol | Consider alternative pain medication if possible |
The mechanism behind several of these interactions involves the liver's cytochrome P450 enzyme system. Ondansetron is primarily metabolized by CYP3A4, CYP2D6, and CYP1A2 enzymes. Drugs that strongly induce these enzymes (such as rifampicin, phenytoin, and carbamazepine) can accelerate ondansetron's metabolism, potentially reducing its antiemetic effectiveness. Conversely, drugs that inhibit these enzymes may increase ondansetron levels, although this is generally of less clinical concern.
The interaction with serotonergic medications deserves particular attention. Serotonin syndrome is a potentially life-threatening condition that can occur when drugs that increase serotonin activity are combined. Symptoms include agitation, confusion, rapid heartbeat, high blood pressure, dilated pupils, muscle twitching, muscle rigidity, loss of coordination, sweating, diarrhea, and in severe cases, hyperthermia and seizures. If you develop any of these symptoms while receiving ondansetron alongside an SSRI or SNRI, seek immediate medical attention.
What Is the Correct Dosage of Ondansetron Hexal?
Ondansetron Hexal is administered intravenously by a healthcare professional. The typical adult dose for chemotherapy is 8 mg before treatment. For surgery, the standard dose is 4 mg given one hour before anesthesia. The maximum single IV dose is 16 mg. Dosing in children is based on body weight.
Ondansetron Hexal is always administered by a doctor or nurse in a clinical setting. The exact dosage depends on the indication (chemotherapy, radiation, or surgery), the patient's age, weight, liver function, and the specific clinical protocol. Always follow your healthcare provider's instructions. The following dosing information serves as a general guide based on established clinical protocols.
Adults – Chemotherapy and Radiation Therapy
Standard Dosing
The usual dose is 8 mg administered as an intravenous injection or infusion immediately before chemotherapy or radiation therapy. Treatment typically continues with ondansetron tablets afterward.
Highly Emetogenic Chemotherapy
For strongly nausea-inducing chemotherapy regimens, ondansetron may be given in one of the following ways:
- 8 mg IV immediately before chemotherapy, followed by additional doses of 8 mg at intervals, up to a maximum daily dose of 32 mg
- Up to 16 mg as a continuous infusion over at least 15 minutes immediately before chemotherapy
A single intravenous dose must not exceed 16 mg. Exceeding this dose increases the risk of serious cardiac rhythm disturbances, including QT prolongation with potentially life-threatening rapid, irregular heartbeat (torsades de pointes). After the first 24 hours, treatment typically transitions to oral ondansetron tablets.
Adults – Postoperative Nausea and Vomiting
Prevention and Treatment
The standard dose is 4 mg as a single intravenous injection administered one hour before the induction of anesthesia. If postoperative nausea or vomiting occurs despite prophylaxis, additional doses may be given as directed by the anesthesiologist.
Elderly Patients
Patients Aged 75 Years and Older
For patients aged 75 years or older, the initial intravenous dose must not exceed 8 mg. This dose may be followed by up to two additional 8 mg intravenous doses given at least 4 hours apart. All intravenous doses in elderly patients should be given as a continuous infusion over at least 15 minutes. Experience with ondansetron in treating postoperative nausea in elderly patients is limited, but the drug is generally well tolerated in patients over 65 years.
Children and Adolescents
Chemotherapy-Induced Nausea (Ages 6 Months to 17 Years)
The dose is individualized and calculated by the physician based on the child's body weight or body surface area. Ondansetron Hexal is administered as an intravenous injection immediately before chemotherapy. The single dose must not exceed 8 mg. When dosing is calculated by body weight, up to two additional intravenous doses may be given at 4-hour intervals. Oral dosing can begin 12 hours later and continue for up to 5 days. The total daily dose must not exceed the adult maximum of 32 mg.
Postoperative Nausea (Ages 1 Month to 17 Years)
The dose is individualized based on body weight. A single dose of ondansetron is given as a slow intravenous injection over at least 30 seconds, at a dose not exceeding 4 mg. This may be given before, during, or after the induction of anesthesia.
Liver Impairment
Patients with moderate to severe liver impairment (hepatic dysfunction) metabolize ondansetron more slowly. In these patients, the total daily dose should not exceed 8 mg, regardless of the indication. Your doctor will adjust the dosing schedule accordingly to prevent accumulation of the drug.
Missed Dose
Since Ondansetron Hexal is administered by healthcare professionals in a clinical setting, missed doses are unlikely. However, if you believe a dose has been missed, inform your doctor or nurse. Do not attempt to administer a dose yourself.
Overdose
Because Ondansetron Hexal is given by medical professionals, overdose is unlikely. However, in the event of an overdose, the following symptoms may occur:
- Visual disturbances (blurred vision, double vision)
- Dizziness and headache
- Drowsiness and fatigue
- Rapid or slow heart rate
- Low blood pressure (hypotension)
- Severe constipation
- Involuntary muscle cramps and twitching
- Restlessness and agitation
- Hallucinations (very rare)
There is no specific antidote for ondansetron overdose. Treatment is supportive and symptomatic. If you suspect an overdose has occurred, notify your healthcare team immediately so appropriate monitoring and treatment can be initiated.
What Are the Side Effects of Ondansetron Hexal?
Like all medicines, Ondansetron Hexal can cause side effects, though not everyone experiences them. The most common side effect is headache (affecting more than 1 in 10 patients). Serious but rare reactions include severe allergic reactions (anaphylaxis), QT prolongation, and transient blindness.
Understanding the potential side effects of a medication helps you recognize problems early and seek appropriate medical care. The side effects of ondansetron are categorized below by their frequency of occurrence, based on data from clinical trials and post-marketing surveillance.
Severe allergic reactions with fever, rash, swelling, and sudden drop in blood pressure (anaphylaxis – rare). Severe widespread skin damage with peeling of the outer skin layer and mucous membranes (toxic epidermal necrolysis – very rare). Sudden chest pain or pressure over the chest (myocardial ischemia). Contact emergency services immediately if you experience any of these symptoms.
Very Common
- Headache
Common
- Sensation of warmth or flushing
- Constipation
- Local reactions at the injection site (with IV administration)
Uncommon
- Movement disorders, involuntary muscle twitching, painful movements
- Oculogyric crisis (eyes forced into a fixed direction, causing dizziness-like sensation)
- Seizures
- Irregular heartbeat (arrhythmia) or slow heartbeat (bradycardia)
- Chest pain
- Low blood pressure (hypotension)
- Hiccups
- Elevated liver enzyme values on liver function tests
Rare and Very Rare
- Hypersensitivity reactions (rare)
- Transient visual changes, including blurred vision – mainly with IV injection (rare)
- Dizziness during rapid IV injection (rare)
- Transient blindness, usually resolving within 20 minutes – mainly with IV injection (very rare)
The cardiac effects of ondansetron are of particular clinical importance. QT prolongation is a change in the heart's electrical activity that can be detected on an electrocardiogram (ECG). While most patients do not experience clinically significant cardiac effects, the risk is increased in patients with pre-existing heart conditions, electrolyte imbalances, or those taking other QT-prolonging medications. This is why the maximum single IV dose is limited to 16 mg.
Serotonin syndrome has been reported when ondansetron is used concomitantly with other serotonergic drugs. Symptoms may include agitation, hallucinations, rapid heartbeat, body temperature changes, loss of coordination, overactive reflexes, nausea, vomiting, and diarrhea. If you experience these symptoms, seek medical attention immediately.
The transient visual disturbances reported with ondansetron are generally associated with intravenous injection rather than oral administration. In the vast majority of cases, these effects resolve spontaneously within minutes to hours without any long-term consequences. If you experience any visual changes during or after receiving Ondansetron Hexal, inform your healthcare provider immediately.
It is important to report suspected side effects after a medicine has been authorized. This makes it possible to continuously monitor the benefit/risk balance of the medicine. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority.
How Should You Store Ondansetron Hexal?
Ondansetron Hexal should be stored in its original outer packaging to protect it from light. Keep it out of the sight and reach of children. Do not use after the expiration date printed on the label or carton.
Proper storage of Ondansetron Hexal is essential to maintain the medication's effectiveness and safety. As a hospital-administered injection, this medication is typically stored and handled by pharmacy and nursing staff. However, understanding proper storage conditions is important for anyone who may handle the medication.
Store the ampoules in the original outer carton to protect them from light, as ondansetron solution is light-sensitive. Do not use the medicine after the expiration date stated on the label or carton after "EXP." The expiration date refers to the last day of that month.
Once opened, the solution should be used immediately. If not used immediately from a microbiological perspective, storage times and conditions prior to and during use are the responsibility of the user and should normally not exceed 24 hours at 2°C to 8°C, unless preparation was carried out under controlled and validated aseptic conditions.
Compatibility with Infusion Solutions
Ondansetron Hexal 2 mg/ml solution for injection may be diluted with the following infusion solutions:
- Sodium chloride 9 mg/ml (0.9%) – normal saline
- Glucose 50 mg/ml (5% w/v) – dextrose
- Ringer's solution for infusion
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures help to protect the environment.
What Does Ondansetron Hexal Contain?
Ondansetron Hexal contains the active substance ondansetron hydrochloride dihydrate (equivalent to 2 mg ondansetron per ml). Inactive ingredients include citric acid monohydrate, sodium citrate dihydrate, sodium chloride, and water for injections.
Understanding the complete composition of your medication is important, particularly if you have known allergies or sensitivities to specific pharmaceutical ingredients. The composition of Ondansetron Hexal is as follows:
Active Substance
The active ingredient is ondansetron hydrochloride dihydrate, present in an amount equivalent to 2 mg of ondansetron per milliliter of solution. Ondansetron is the pharmacologically active component responsible for the antiemetic effect. The hydrochloride salt form enhances the drug's solubility in water, making it suitable for injectable formulations.
Inactive Ingredients (Excipients)
- Citric acid monohydrate (E 330): A buffering agent that helps maintain the correct pH of the solution, ensuring stability and tolerability upon injection.
- Sodium citrate dihydrate (E 331): Works in conjunction with citric acid as part of the buffer system to maintain solution pH within the optimal range.
- Sodium chloride: Adjusts the tonicity (osmotic pressure) of the solution to make it compatible with blood and body fluids, reducing pain and tissue irritation at the injection site.
- Water for injections: Highly purified water that serves as the solvent, meeting strict pharmacopoeial standards for injectable preparations.
Appearance and Packaging
Ondansetron Hexal is a clear solution supplied in glass ampoules. Available pack sizes include 5 × 2 ml, 25 × 2 ml, 5 × 4 ml, and 25 × 4 ml ampoules. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Ondansetron Hexal
Ondansetron Hexal is a prescription injection used to prevent and treat nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. It contains ondansetron, a serotonin 5-HT3 receptor antagonist that blocks the chemical signals in the body responsible for triggering the nausea and vomiting reflex. It is approved for use in adults and children (from 6 months for chemotherapy-related nausea; from 1 month for postoperative nausea).
The most common side effect is headache, affecting more than 1 in 10 patients. Other common side effects include sensation of warmth or flushing, constipation, and local reactions at the injection site. Less common but clinically important side effects include irregular heartbeat, seizures, chest pain, low blood pressure, and hiccups. Rare side effects include transient visual changes and dizziness during rapid injection.
Ondansetron Hexal should not be used during the first three months of pregnancy (first trimester) because it may slightly increase the risk of cleft lip and/or cleft palate in the baby. If you are pregnant, think you may be pregnant, or are planning to become pregnant, speak with your doctor before receiving this medication. Women of childbearing age may be advised to use contraception during treatment.
Ondansetron Hexal must never be used with apomorphine (a Parkinson's disease medication) due to the risk of severe low blood pressure and loss of consciousness. Caution is also needed with SSRIs and SNRIs (risk of serotonin syndrome), tramadol (reduced pain relief), phenytoin, carbamazepine, and rifampicin (which may reduce ondansetron's effectiveness), QT-prolonging drugs, and anthracyclines (increased cardiac risk).
A single intravenous dose must not exceed 16 mg due to the increased risk of serious cardiac rhythm disturbances (QT prolongation). The maximum total daily dose is 32 mg. For elderly patients aged 75 and older, the initial IV dose should not exceed 8 mg. For patients with moderate to severe liver impairment, the total daily dose should not exceed 8 mg.
Ondansetron Hexal works by selectively blocking serotonin 5-HT3 receptors. Chemotherapy drugs, radiation, and anesthesia trigger the release of serotonin from enterochromaffin cells in the small intestine. This serotonin normally binds to 5-HT3 receptors on vagal nerve endings, sending signals to the brain's vomiting center. By blocking these receptors, ondansetron prevents the nausea and vomiting signals from being transmitted, providing effective relief.
References
- World Health Organization. WHO Model List of Essential Medicines – 23rd list, 2023. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Ondansetron – Summary of Product Characteristics. EMA/CHMP; Updated 2024.
- Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology. 2020;38(24):2782-2797.
- Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. Annals of Oncology. 2016;27(suppl 5):v119-v133.
- Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. New England Journal of Medicine. 2006;354(16):1698-1705.
- Tricco AC, Blondal E, Veroniki AA, et al. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Medicine. 2016;14:216.
- Danielsson B, Wikner BN, Kallen B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reproductive Toxicology. 2014;50:134-137.
- British National Formulary (BNF). Ondansetron. NICE Evidence Services; Updated 2025.
- U.S. Food and Drug Administration (FDA). Zofran (ondansetron) prescribing information. Silver Spring, MD: FDA; Updated 2023.
- Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesthesia & Analgesia. 2020;131(2):411-448.
About the Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians with expertise in pharmacology, oncology, and clinical medicine. Our editorial process follows the GRADE evidence framework and adheres to international medical guidelines from WHO, EMA, FDA, and other authoritative bodies.
All medical claims in this article are supported by peer-reviewed research and international guidelines. Evidence level: 1A (highest quality).
iMedic has no commercial funding or pharmaceutical sponsorship. All content is editorially independent.
This article was last medically reviewed on . We update our content when new evidence emerges.
This page meets WCAG 2.2 Level AAA accessibility standards, ensuring information is available to everyone.